MARKET

MYGN

MYGN

Myriad Genetics
NASDAQ
19.17
+0.32
+1.70%
After Hours: 19.17 0 0.00% 16:01 11/29 EST
OPEN
18.83
PREV CLOSE
18.85
HIGH
19.35
LOW
18.69
VOLUME
754.15K
TURNOVER
0
52 WEEK HIGH
28.45
52 WEEK LOW
15.38
MARKET CAP
1.55B
P/E (TTM)
-20.6707
1D
5D
1M
3M
1Y
5Y
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41st Annual Natio...
GlobeNewswire · 11/14 13:00
New Study Published In JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments For Women Of All Ancestries
Benzinga · 11/03 22:01
Myriad Genetics (MYGN) Q3 Earnings Miss, Gross Margin Falls
Myriad Genetics (MYGN) hereditary cancer testing volume returns to growth in the third quarter. GeneSight comes up with yet another strong performance.
Zacks · 11/03 15:59
--SVB Securities Adjusts Price Target on Myriad Genetics to $25 From $27, Maintains Market Perform Rating
--SVB Securities Adjusts Price Target on Myriad Genetics to $25 From $27, Maintains Market Perform Rating
MT Newswires · 11/02 12:40
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Benzinga · 11/02 09:07
SVB Leerink Maintains Market Perform on Myriad Genetics, Lowers Price Target to $25
Benzinga · 11/02 09:06
Nasdaq Down 60 Points; Eli Lilly Lowers Earnings Forecast
Benzinga · 11/01 18:57
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/01 18:10
More
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing the disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression, and includes corporate services, such as finance, human resources, legal and information technology. The Company discovers and commercializes genetic tests. The Company's products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight and Prequel, GeneSight, Vectra. The Company offers SneakPeek Early Gender DNA Test, which reveals a baby’s gender at six weeks into pregnancy. Its wholly owned subsidiaries include Myriad Genetic Laboratories, Inc., Assurex Health, Inc. and Myriad Women’s Health, Inc.

Webull offers kinds of Myriad Genetics, Inc. stock information, including NASDAQ:MYGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYGN stock methods without spending real money on the virtual paper trading platform.